Drug development for neurodegenerative diseases.
既承認薬を有効活用したiPS創薬により見出された難治性疾患の根本治療薬 現在、難治性疾患であるアルツハイマー病は、対症療法薬しかなく、大きな社会問題になっています。特に家族性アルツハイマー病の方は、...
契約に関わる技術内容について 本特許は、京都大学が出願した特許であり、京都大学iPS細胞研究所で開発された技術をもとに、薬剤スクリーニングを実施し発見された化合物に関わるもので、アルツハイマー病に対...
HOIST is developing anti-cancer products with novel mechanism-of-action utilizing the MA-T® system. Further, we are pursuing epitranscriptomics drug discovery via a novel target, ALKBH. In addition, we run a drug discovery support business for our clients creating patient derived cells (PDC) / patient derived xenografts (PDX). In pharmaceutical development, HOIST aims to utilize partnerships with pharmaceutical companies (via licensing-out, joint drug discovery etc.). In the drug discovery support business, we tailor PDC/PDX solutions to individual needs of our clients, and contribute to higher success rate of product development.
A startup leveraging its proprietary language processing technology, SATOMI®, to support the automatic generation of medical records and referral letters. By streamlining information use in clinical settings, it promotes regional collaboration and medical DX, contributing to the development of a sustainable healthcare system.
A Tokushima University-spinoff startup developing digital dental crown technology that treats teeth without grinding healthy enamel. By designing crowns that only replace necessary parts, it provides solutions to dental clinics, with adoption at 250 clinics nationwide, contributing to reduced patient costs and improved treatment precision.
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
